P858: FUNCTIONAL STUDIES IN MULTIPLE MYELOMA CELL LINESWITH OVEREXPRESSION OF NRAS Q61R MUTATION

P858: FUNCTIONAL STUDIES IN MULTIPLE MYELOMA CELL LINESWITH OVEREXPRESSION OF NRAS Q61R MUTATION

Bibliographic Details
Main Authors:	Romano Liotti, Angelica Macauda, Rainer Will, Stefano Landi, Federica Gemignani, Federico Canzian
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970336.69607.62

Similar Items

Giant congenital melanocytic naevus caused by NRAS Q61K mosaicism
by: Carl M. Thielmann, et al.
Published: (2022-12-01)

Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II
by: Teklab Gebregiworgis, et al.
Published: (2024-06-01)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy
by: Kimberley McGrail, et al.
Published: (2022-11-01)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
by: M. Shokouhi, et al.
Published: (2022-06-01)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
by: Federica Morani, et al.
Published: (2021-03-01)

Liquid Biopsy with Detection of NRAS<sup>Q61K</sup> Mutation in Cerebrospinal Fluid: An Alternative Tool for the Diagnosis of Primary Pediatric Leptomeningeal Melanoma
by: Angela Mastronuzzi, et al.
Published: (2022-07-01)

PB1958: IN SILICO ANALYSIS OF SYNONYMOUS AND NON-SYNONYMOUS SNPS OF THE HUMAN CEREBLON (CRBN) GENE: AN IMPORTANT GENE IN IMMUNOMODULATORY DRUGS (IMIDS)-BASED TREATMENT OF MULTIPLE MYELOMA PATIENTS
by: M. Güler, et al.
Published: (2022-06-01)

Identification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis
by: Sophie Klemm, et al.
Published: (2023-11-01)

Deciphering Conformational Changes of the GDP-Bound NRAS Induced by Mutations G13D, Q61R, and C118S through Gaussian Accelerated Molecular Dynamic Simulations
by: Zhiping Yu, et al.
Published: (2022-08-01)

P858: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR T-CELL CYTOTOXICITY
by: L. Martinez-Verbo, et al.
Published: (2022-06-01)

Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody
by: Lin Gui, et al.
Published: (2023-04-01)

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
by: Manuel Croix, et al.
Published: (2023-08-01)

Action of Light on Metabolism of Yeast FT-858
by: Maria do Socorro Mascarenhas Santos, et al.
Published: (2019-09-01)

The Sec61 translocon is a therapeutic vulnerability in multiple myeloma
by: Antoine Domenger, et al.
Published: (2022-03-01)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
by: Rodney Shackelford, et al.
Published: (2014-05-01)

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated <i>NRAS<sup>Q61R/K/L</sup></i> Mutant Melanoma (TraMel-WT)
by: Gil Awada, et al.
Published: (2021-04-01)

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
by: Fidler, C, et al.
Published: (2004)

NRAS destines tumor cells to the lungs
by: Giannou, AD, et al.
Published: (2017)

NRAS mutation in differentiated thyroid cancer
by: Saswata Saha, et al.
Published: (2022-01-01)

Effect of Cryogenic Treatment on the Properties of Low Carbon A858 Steel
by: Abbas A. Hussein, et al.
Published: (2023-07-01)

miR-145-5p suppresses cell proliferation by targeting IGF1R and NRAS genes in multiple myeloma cells
by: Kaya Murat, et al.
Published: (2023-06-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01)

الملک الاشوری شلمنصر الثالث (858-824 ق.م) - (رسالة ماجستیر)
by: حسین النجم, et al.
Published: (2003-06-01)

Advances in the treatment of advanced melanoma with NRAS gene mutation
by: ZHAO Bolun, ZHU Guannan
Published: (2023-10-01)

NSO myeloma cell death: Influence of bcl-2 overexpression.
by: Murray, K, et al.
Published: (1996)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
by: Antoine Domenger, et al.
Published: (2023-01-01)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
by: Guangrui Li, et al.
Published: (2023-10-01)

GWAS-Identified Variants for Obesity Do Not Influence the Risk of Developing Multiple Myeloma: A Population-Based Study and Meta-Analysis
by: José Manuel Sánchez-Maldonado, et al.
Published: (2023-03-01)

Inherited genetic variants associated with melanoma BRAF/NRAS subtypes
by: Thomas, NE, et al.
Published: (2018)

NRAS and BRAF mutation frequency in primary oral mucosal melanoma
by: Buery, R.R., et al.
Published: (2011)

JMML WITH NRAS MUTATION IN ELANE ASSOCIATED SEVERE CONGENITAL NEUTROPENIA
by: Hilde Hylland Uhlving, et al.
Published: (2023-12-01)

Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis
by: Haruhiko Takahashi, et al.
Published: (2024-01-01)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
by: Amanda S. Hirata, et al.
Published: (2021-12-01)

NRAS-driven melanoma: A RAF can hide another
by: Sabine Druillennec, et al.
Published: (2017-11-01)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
by: L. Hasan Bou Issa, et al.
Published: (2022-06-01)

Evaluation of Metabolites and Amino Acids Assimilation by Yeast FT-858 in Saccharine Substrates for the Production of Bioethanolroduction
by: Larissa Pires Mueller, et al.
Published: (2019-09-01)

Block transitive 2—（v，6，1） designs and the classical simple groups PSpn (q)(区传递的2-（v，6，1）设计与典型单群PSpn(q))
by: ZHANGCaihong(张彩红), et al.
Published: (2018-11-01)

PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA.
by: Hedda Monsen, et al.
Published: (2023-08-01)

Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis
by: Yin, C, et al.
Published: (2019)

Identification of <i>NRAS</i> Downstream Genes with CRISPR Activation Screening
by: Akiya Tatsumi, et al.
Published: (2022-10-01)